MedPage Today October 24, 2024
— Study also showed that patients were more likely to receive timely treatment
Women with newly diagnosed hormone receptor (HR)-negative, HER2-positive breast cancer were more likely to receive timely treatment and have longer survival in states that participated in Medicaid expansion under the Affordable Care Act, a nationwide study showed.
For over 31,000 women with this aggressive breast cancer, Medicaid expansion was associated with an increase of 0.58 percentage points in receipt of guideline-concordant treatment overall, an increase of 2.43 percentage points in initiation of guideline-concordant treatment less than 60 days after diagnosis, and an increase of 1.17 percentage points in the 2-year survival rate, reported Kewei Sylvia Shi, MPH, of the American Cancer Society, and colleagues.
The biggest increase...
Today's Sponsors
Today's Sponsor